Accessibility: Skip TopNav
Primo Biotechnology Secures A Funding and Targets 2026 IPO
To enhance strengthen global radiopharmaceutical strategy and innovation of precision medicine
Format
JPEG
Source
Primo Biotechnology Co., Ltd.
Downloads
Original
Large
Medium
Small